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1. Introduction
Ischemia (from the Greek ισχαιμία, ischaimía; isch- root denoting a restriction or thinning or
to make or grow thin, haema blood) is the restriction of blood supply and thus the inadequate
delivery of oxygen and removal of carbon dioxide from cellular tissue. This imbalance may
lead to dysfunctional or permanent damage to the affected tissue and organ.
Cardiac ischemia occurs when there is a supply versus demand mismatch in coronary blood
flow. In patients who present with unstable angina, ischemia occurs due to partial or total
occlusion of a coronary artery due to plaque rupture. In stable angina however, there is
progressive vascular occlusion resulting ultimately in a luminal stenosis of greater than 70%,
impeding blood flow to the distal tissue. If the ischemia is reversible, no permanent myocardial
damage occurs.If however the ischemic episode is prolonged; there will be cellular necrosis
which will lead to acute myocardial infarction (AMI).The immediate clinical challenge is to be
able to identify acutely impaired myocardial perfusion before the necrotic process starts.
Currently, the only strategy for this is to detect ST-segment changes on the electrocardiogram
(ECG), however the ECG is non-diagnostic in many cases. The sensitivity of the admission
ECG for the diagnosis of AMI is typically around 50%. Reperfusion, be it pharmacological or
surgical, is the essential life-saving intervention with the aim of salvaging myocardial tissue
localised at the affected site. Many patients however who present with chest pain to the
emergency department (ED) do not have a final diagnosis of AMI. There is therefore a need
for a strategy which could detect cardiac ischemia before necrosis occurs and result in prompt
revascularisation. Blood borne biomarkers for ischemia may be of diagnostic and prognostic
value.
To date, a number of candidate biomarkers of ischemia are being researched. However, one,
Ischemia modified albumin (IMA®), has been developed into a commercially available cardiac
biomarker assay and licensed for routine clinical application both by CE marking in Europe
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and Food and Drug Administration (FDA) approval in the United States. This chapter will
explore the rational for the necessity of cardiac ischemia biomarker testing and detail the
development of the IMA assay with emphasis on its clinical and prognostic utility.
1.1. The cardiovascular disease epidemic
Cardiovascular disease (CVD) accounts for the majority of global deaths. CVD was responsible
for 29% of all global deaths in 2004. According to the World Heart Federation, CVD is
responsible for 17.1 million deaths globally each year. Surprisingly, 82% of these deaths occur
in the developing world. Such numbers are often difficult to comprehend. CVD is responsible
for one in every five deaths disease kills one person every 34 seconds in the USA alone. 35
people under the age of 65 die prematurely in the United Kingdom every day due to CVD. It
is predicted that by 2030 23 million people will die annually from a cardiovascular related
disease. Data from the USA suggests that CVD was responsible for 34% of all deaths in 2006
and over 151,000 Americans who died were under 65 years of age.
1.2. Acute chest pain
Patients with chest pain constitute the largest single category of patients admitted to hospitals
in the UK [1]. In the USA, registry data recorded 11.2 million chest pain presentations to the
ED in 2008 alone. The presentations are also diagnostically challenging. The majority of
admissions have either stable ischemic heart disease (IHD) or no ischemic heart disease [2].
Such admission episodes are often short and clinically inappropriate. Conversely, it has been
estimated that between 2 and 7% of patients with AMI are inappropriately discharged from
the ED [3, 4] and suffer disproportionate morbidity and mortality. Attempts to improve
diagnosis have included risk scoring systems [5], computerised decision support [6, 7] and
automated ECG interpretation [8]. Although clinical assessment remains integral to the
assessment of patients with chest pain, cardiac biomarker measurement has become an
essential component in the diagnostic armamentarium.
2. Pathophysiology of cardiac ischemia
The mechanisms involved in the development of cardiovascular disease are multifactorial and
include abnormalities in cholesterol and lipid metabolism, inflammation and oxidative stress
processes within the vascular wall, cellular disruption to the endothelium and intra-lumenal
platelet activation/aggregation. The ischemia cascade from initiation of local ischemia to the
development of symptomatic chest pain is depicted in figure 1.The pathological processes
responsible for the development of atherosclerotic lesions and endothelial dysfunction are
advanced far earlier than when patients typically become symptomatic and present with chest
pain. The disease process does not occur in distinct episodes but rather is a continuum from
asymptomatic vascular dysfunction thorough to angina in those with myocardial ischemia,
which, without intervention can progress to non-ST segment elevation myocardial infarction
(NSTEMI) or cumulate into ST segment elevation myocardial infarction (STEMI). Patients
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presenting at any stage in the process may be diagnosed with acute coronary syndrome (ACS).
The earlier in the disease continuum the presentation is; the greater the opportunity for
successful myocardial tissue preservation. As there is no definitive biomarker for ischemia,
current treatment focuses on the need for urgent therapeutic revascularisation in patients with
established cardiac necrosis, identified by the cardiac troponins.
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Figure 1. Development of Ischemia in the ischemia cascade.
The pathological process unless disrupted by therapeutic intervention results in the death of
cardiac myocytes. Predisposing this terminal event, a vulnerable atherosclerotic plaque
becomes disrupted exposing the thrombogenic lipid core and sub endothelium to the luminal
milieu. Exposure results in platelet activation and aggregation and along with the coagulation
cascade, an intracoronary thrombus forms. The thrombus may not obstruct the lumen and the
patient is asymptomatic, however if the lumen is totally occluded, AMI will ensue. A partially
occluded lumen and reduced oxygen supply both contribute to the development of ischemic
myocardium.
3. Clinical detection of cardiac ischemia
The clinical presentation of cardiac ischemia is difficult to definitively diagnose. Currently
there is no gold standard test to detect ischemia however a number of reliable tests exist.
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Historically patients were admitted for monitoring or discharged on the basis of clinical
interpretation by the ED physician. It is accepted that this is no longer acceptable clinical
practice.
The typical presentation is exertional or stress induced central chest pain. These episodes
usually last from a few minutes to hours and can resolve upon rest. Common descriptions by
the patient include tightness, crushing stabbing or burning pain. Patients may also have nausea
and vomiting, dyspnoea, palpitations. Typical symptoms increase the likelihood of an AMI
however atypical presentations cannot be used to exclude AMI. Women, the elderly and those
with diabetes mellitus often present with atypical chest pain.
The clinical history and physical examination will assess the presence of risk factors for AMI,
however alone; the initial clinical examination is insensitive and unspecific for diagnosis. It
may however give insight to differential or alternative diagnoses in those patients who, upon
further investigation do not have an AMI. The 12 lead ECG is additive to the physical exami‐
nation. The majority of ECG traces performed at admission are non-diagnostic with approxi‐
mately 5% of suspected AMI patients having a diagnostic trace indicative of AMI. Although
the ECG is relatively insensitive, the presence of ST segment elevation however is 100%
diagnostic for AMI and serves as the criterion for immediate induction of fibrinolytic therapy
or emergency interventional revascularization.
3.1. Cardiac imaging
Recently cardiac imaging has played an important role in the detection of ischemia. Perfusion
abnormalities can be detected by single-photon emission computer tomography (SPECT)
myocardial perfusion imaging (MPI) and mechanical dysfunction can be detected by echo‐
cardiography or gated MPI. Gated SPECT MPI can identify regional and global dysfunction
of the left ventricle as ischemia impairs myocellular contractility. SPECT requires uptake of an
isotope by active membrane transport mechanisms and caution should be advised in those
patients with impaired renal clearance. Both echocardiography and SPECT are sensitive and
specific and have a high negative predictive value for the diagnosis and prognosis of patients
with suspected ACS. These diagnostic modalities however are grossly expensive, time
consuming, technically more challenging and are not as widely available as compared to the
simple ECG or a blood borne biomarker. The use cardiac imaging in the ED on a 24 hour, 7
day a week basis is therefore compromised.
3.2. Cardiac biomarkers of ischemia
There have been progressive developments within basic and clinical research to identify
candidate biomarkers of ischemia and to develop simple to use assays. Any such assay needs
to have similar analytical (limit of detection, precision, reference intervals) and clinical
performance (sensitivity, specificity, risk stratification and predictive value) compared to that
of markers of necrosis, such as high sensitivity cardiac troponin assays. A number of candidate
biomarkers have been identified. However very few make it from a research grade assay to a
fully licenced automated assay for clinical use. The most promising biomarkers to date are
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reviewed below. Of these, Ischemia Modified Albumin has been the most successful biomarker
and greater attention is given to this marker.
4. Malondialdehyde low density lipoprotein
Malondialdehyde low density lipoprotein (MDA-LDL) is a sensitive biomarker for ACS
patients with unstable angina and AMI. MDA is a candidate compound which causes oxidative
modification of LDL. MDA (propanedial, C3H4O2) is a reactive aldehyde produced by degra‐
dation of polyunsaturated lipids or released during prostanoid metabolism. This reactive
oxygen species causes oxidative modification to LDL. MDA-LDL reacts with the charged
amino group of B-100 protein lysyl residues. Plasma concentrations of MDA-LDL identify
patients with coronary artery disease. Modified LDL may also instigate an immune response
leading to autoantibody and LDL immune complex production. MDA-LDL not only serves as
an oxidative stress marker but as a marker of plaque destabilisation.
5. Myeloperoxidase
Myeloperoxidase (MPO, EC 1.11.2.2, 1.11.2.2) is a 150 KDa protein dimer consisting of two 15
KDa light chains and two variable weight glycosylated heavy chains bound by a heme group
responsible for the green colour when secreted in pus and mucus. There are three known
isoforms which differ in the size of the heavy chain [9]. It is encoded by the MPO gene located
on chromosome 17 [10]. MPO is most abundant in neutrophil granulocytes. It is a lysosomal
enzyme stored in azurophilic granules of polymorphonucleocytes and macrophages. MPO
catalyses the conversion of chloride and hydrogen peroxide into hypochlorite (hypochlorous
acid). Furthermore, MPO oxidises tyrosine to the tyrosyl radical using hydrogen peroxide as
an oxidising agent. Both hypochlorite and the tyrosyl radical are cytotoxic and are produce to
kill pathogens in response to infection. Elevation in MPO is therefore not indicative of cardiac
ischemia, as increases occur in infection, inflammation and infiltrative disease processes, thus
reducing the specificity for cardiac ischemia.
MPO may contribute to the pathophysiology of ACS, as the hypochlorite end product is an
oxidizing agent of low density lipoprotein (LDL) and may play a key role in the degradation
of collagen and contributing to the destabilisation of the plaque. Patients with ACS who have
elevated MPO are at risk of short and long-term adverse outcomes. In a case-control study
from the USA, Zhang and colleagues demonstrate that MPO concentrations are significantly
greater in patients (n=158) with coronary artery disease compared to controls (n=175) who do
not demonstrate angiographically significant coronary disease [11]. Plasma MPO concentra‐
tions identify patients at risk of major adverse cardiac events in the absence of necrosis. In 604
sequential chest pain admissions, MPO predicted adverse cardiac events (AMI, need for
revascularisation or death)at 30 days (odds ratio 2.2, 95%CI 1.1-4.6) and 6 months (odds ratio
4.1, 95%CI 2.0-8.4) [12].
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6. Whole blood choline
Choline (2-hydroxy-N,N,N-trimethylethanaminium, C5H11NO) is a water soluble essential
nutrient. It is a product of phosphodiesteric cleavage of membrane phospholipids such as
phosphatidylcholine and sphingomyelin; catalysed by phospholipase D (EC 3.1.4.4). Choline
is the precursor to actylcholine production.
Physiologically choline provides cell structural integrity, is the precursor for acetylcholine
production and a source of methyl groups that participate in the S-adenosylmethionine
synthesis pathway.
Whole blood (WBCHO) and plasma choline concentrations increase after stimulation of
phospholipase D and the activation of coronary plaque cell surface receptors or ischemia.
Phospholipase D activation in coronary plaques causes stimulation of macrophage by oxidised
LDL, secretion of matrix metalloproteinase enzymes and activation of platelets. WBCHO can
be measured by high performance liquid chromatography coupled to mass spectrometry
(HPLC-MS). In a study of over 300 patients with suspected ACS, WBCHO measured at
admission was a significant predictor of cardiac death, cardiac arrest, arrhythmia, heart failure
or the need for percutaneous coronary intervention (PCI) at 30 day follow up [13]. The
predictive power was enhanced by the addition of either cTnT or cTnI and served not as a
marker of myocardial cell necrosis but identified patients at high risk with unstable angina.
WBCHO is therefore a better predictive tool than plasma choline for early risk stratification in
patients who are cardiac troponin negative on admission. The current detection methodology
using HPLC-MS is not suitable for urgent clinical use.
7. Free fatty acids
Fatty acids are carboxylic acid molecules with a long aliphatic tail known as a chain, which are
either saturated or unsaturated. Most naturally occurring fatty acids have an even number of
carbon atoms (4 to 28) in the tail region. Fatty acids are produced from the breakdown of
triglyceride or phospholipid. The majority fatty acids circulate bound to albumin with a very
small percentage appearing as the unbound free fatty acid (FFAu) form [14]. The circulating
level of FFA is limited to the availability of the albumin binding sites.
The mechanism of FFAu release is not fully understood however increased catecholamines
following cardiac ischemia may activate FFAu release following lipolysis in adipocytes. FFAu
are 14-fold higher post-PCI, compared to pre procedural concentrations and were higher in
those with associated ischemic ST segment changes [15]. A recombinant fatty acid binding
protein bound to a fluorescent tag (ADIFAB) [16;17] has been developed and a second
generation assay using a fluorescent molecular probe (ADIFAB2] and a portable reader makes
this a potential early marker for the point of care setting. Whilst this marker shows promise in
the early phase of ischemia induced ACS, further trials are required to evaluate the diagnosis
and prognostic value of FFAu in the chest pain population.
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8. Ischemia modified albumin
The NH2-terminal of human serum albumin (HSA, 66.5 kDa, 585 amino acids) is known to be a
binding site for transition metal ions such as cobalt, copper and nickel [18]. Using one and two
dimensional 1H-NMR studies, Sadler and colleagues demonstrated binding of Ni++, Cu++, Co++,
Cd++ and Al+++ to bovine and human serum albumin. Strong binding was associated with three
N-terminal amino acid residues (Asp-Thr-His in bovine albumin and Asp-Ala-His in human
albumin). A Lysine residue designated Lys4 is also involved in the binding site. The authors
demonstrated for the fist time selective reduction in the intensities of resonances to the εCH2
resonance of Lys4 on the addition of Co++ to HSA. There are in fact, four metal-binding sites with
different specificities in HSA. In addition to the NH2-terminal, three other sites occur at (i) reduced
cysteine at residue Cys34, (ii) site A, including histidine at His67 as a ligand and (iii) the non-
localized site B. Cu++ and Ni++ preferentially bind the NH2-terminus site. Cd++ bind sites A and B,
Zn++ binds site A and Au+ and Pt++ bind at residue Cys34.
A reduction in oxygen supply causes localized acidosis and the generation of free radicals.
Copper and zinc ions, normally bound to proteins in the plasma are released from protein
binding sites to circulate in the free form [19-21]. The N-terminus of albumin binds transition
metals. The N-terminus however, is susceptible to biochemical alteration [22]. The altered form
is referred to as ischemia modified albumin (IMA). Following a period of ischemia, a reduction
in the ability of albumin to bind cobalt is apparent. This is the basis of the albumin cobalt-
binding test (ACB® test) for IMA. IMA has been extensively studied in the basic science and
clinical research settings and is an FDA cleared CE marked clinical assay for the detection of
cardiac ischemia.
It is currently not known if there are any significant changes in total human serum albumin
between ischemic and non ischemic patients in the general chest pain population. Many
divalent metals bind HSA in the circulation but in concentrations far lower than that required
to impact albumin directly. The N-terminal portion of HSA is susceptible to biochemical
degradation and is less stable than the albumin of other species [22] including bovine, dog,
goat, horse, pig rabbit, rat and sheep but not chicken. Using electrospray-mass spectrometry
and N-terminal sequencing, Chan and colleagues have demonstrated degradation corre‐
sponding to the first two resides (Asp-Ala) which is dependent both on temperature and the
N-terminal alpha-amino group.
IMA however is a form of HSA where the N-terminal amino acids are unable to bind transition
metal ions. Myocardial ischemia is known to generate free radicals [21;23], induce localised
acidosis [20] and the release of free iron and copper ions bound to enzymes and proteins.
[19;24]. Direct evidence of Cu/Fe mobilization in the coronary flow following prolonged (25-60
minute) ischemia but not short (15-21 minute) ischemia has been demonstrated [24]. Both
copper and iron concentrations in the first coronary flow fraction were 50-fold and 15-fold
higher respectively following prolonged ischemia, compared to pre-ischemic concentrations.
This suggests that both copper and iron play a causative role in ischemic cardiac injury by their
ability to catalyse the production of free radicals and could be the target of therapeutic
intervention to salvage tissue damage [19]. It was therefore postulated that following a period
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of cardiac ischemia, these processes would result in a change in the ability of the N-terminus
of HSA to bind transition metal ions. The release of these ions likely initiates one potential
pathway for IMA generation, rather than be considered an interference that may negatively
affect IMA. In support of this suggestion, decreased albumin cobalt binding was reported in
99 acute chest pain patients with myocardial ischemia [25] compared to 44 chest pain patients
with no evidence of myocardial ischemia. Albumin cobalt binding was also assessed in 41
patients undergoing elective coronary artery angioplasty. Samples were tested using the
Albumin Cobalt Binding (ACB) assay before, immediately after, 6 and 24 hours post procedure
and compared to results from 13 patients undergoing cardiac catheterization without balloon
angioplasty, thus serving as the control group. ACB concentrations were significantly elevated
immediately post procedure, compared to the control population and ACB concentrations
returned to baseline after six hours [26]; suggesting that HSA undergoes a significant reduction
in the capacity to bind exogenous Co++ immediately after coronary artery occlusion induced
during elective angioplasty. Modification of the Asp-Ala-His-Lys site by N-terminal acetyla‐
tion or deletion of one or more residues abolishes this cobalt binding [27].
The postulated mechanism (figure 2) of IMA generation is that localised ischemia results in
acidosis. The localised acidotic environment stimulates the release of Cu++ ions from weak
binding sites on circulating proteins such as caeruloplasmin. Caeruloplasmin (EC 1.16.3.1,
151kDa) is a ferroxidase enzyme encoded by the CP gene located on Chromosome 3. The
enzyme is synthesised in the liver and carries approximately 70% of the total copper in human
plasma (a further 15% carried by HSA and the remainder by macroglobulins). Each enzyme
molecule contains 6 atoms of copper within its structure.
In the presence of a reducing agent such as ascorbic acid, free copper II  is converted to
copper I which can react with oxygen to form copper II and generate superoxide free radicals
(O2 •–). Superoxide dismutase (EC 1.15.1.1) converts the superoxide free radical to hydro‐
gen peroxide which is then degraded by catalase. The copper II ions released are immediate‐
ly scavenged by human serum albumin but they are tightly bound to the N-terminus. Copper
bound albumin is then damaged by hydroxyl free radicals (OH •), causing removal of the
three N terminal amino acids and release of the copper II ion to repeat the process in a
chain reaction [28].Marx and Chevion demonstrated by SDS/polyacrylaminde gel electropho‐
resis the site specific alteration of HSA in the presence of 50 μM Cu++ and increasing portions
of 0.2 m Mascorbate; where after the addition of 5 portions, bands at 3, 18, 22, 47 and 50
kDa were observed. The authors also demonstrated that degradation does not occur in the
absence of Cu++ or in the addition of 1 m Methylenediaminetetraacetic acid (EDTA) or citrate
chelating agents [28].
This postulated mechanism, although theoretically attractive has not been borne out in
practice. In a study of patients with increased IMA, the N-terminal portion of albumin was
sequenced in 8 cases [29] by cleavage of the 11 amino acid resides at the NH2 terminus, by
rapid liquid-phase Edman degradation. The N-terminal amino acid sequence showed normal
residues for 6 of 7 patient samples with elevated IMA and one non-ischemic sample (table 1).
The remaining patient sample with high IMA demonstrated two missing amino acids at the
N-terminus. Clinically this patient did not have an ischemic cardiac event.
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Subject NH2-terminal HSA Sequence
Control (wild type) DAHKSEVAHRF
Non-ischemic patient, high serum IMA ----HKSEVAHRF
Ischemic patient, high serum IMA DAHKSEVAHRF
Ischemic patient, high serum IMA DAHKSEVAHRF
Ischemic patient, high serum IMA DAHKSEVAHRF
Ischemic patient, high serum IMA DAHKSEVAHRF
Ischemic patient, high serum IMA DAHKSEVAHRF
Ischemic patient, high serum IMA DAHKSEVAHRF
Table 1. Amino (NH2) terminal sequence analysis of human serum albumin (HAS) from 6 ischemic patients, a control
(wild type) and one non ischemic patient with a high serum IMA concentration. (Source: Adapted from Bhagavan et
al, ClinChem 2003;49:581-585)
The in vivo half-life of HSA is 19-20 days. HSA with a truncated NH2-terminus would pre‐
sumably have similar in vivo half life properties and yet IMA returns to baseline rapidly after
an ischaemic cardiac event. This indicates that the alteration to albumin to create IMA is
transient and reversible, rather than a finite chemical alteration. Recent physicochemical
Figure 2. Mechanism of Ischemia Modified Albumin generation. [1]Tissue hypoxia from anaerobic metabolism re‐
duces ATP and causes a [2]lower localized pH inducing acidosis. [3]Cu++ ions are released from plasma proteins such as
caeruloplasmin. In the presence of ascorbic acid, [4]Cu++ is converted to Cu+. Cu+ reacts with O2 to form [5]O2 •–. Super‐
oxide dismutase dismutates the O2 •– to [6]H2O2, which in presence of Cu++ or Fe+, undergoes the Fenton reaction
forming [7]OH •hydroxyl radicals. Free Cu++ is scavenged by [8]HSA, where it binds tightly to the N-terminus. OH • radi‐
cals alter the amino acid N-terminus of [9]HSA rendering it incapable of binding Cu++. These two altered forms are
known as IMA.
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studies using electronic absorption EPR and NMR spectroscopy of Co-binding to HSA under
anaerobic conditions to prevent Co++ oxidation have suggested a different explanation. Using
competition experiments with cadmium (Cd++) which binds sites A and B and Cu++ which binds
the NH2-terminus, three binding sites for Co++ were identified on HSA. Sites A and B showed
greater avidity for Co++ binding than the NH2-terminal binding site [30]. Fatty acid binding to
albumin occurs at one of the additional cobalt binding sites with a negative allosteric interac‐
tion. It is hypothesised, that in myocardial ischemia the release of fatty acids results in binding
of fatty acids to albumin. This would then reduce the ability of albumin to take up cobalt hence
account for the presence of IMA [30]. If this also produced a conformational change in the
albumin affecting the N terminal site, this would also reduce cobalt binding.
8.1. Kinetic release of ischemia modified albumin
Studies in patients receiving angioplasty where ischemia is induced in a controlled manner,
have defined the kinetics of IMA production. There is a rapid rise in IMA values after balloon
inflation with a subsequent fall at 6 hours and return to normal by 24 hours [31;32]. The rise
in IMA occurs earlier than the rise in cardiac troponin and natriuretic peptides (figure 3) and
occurs early after the onset of plaque rupture.
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Figure 3. Kinetic release of Ischemia modified albumin (IMA, dotted line) and other cardiac markers, cardiac tropo‐
nin (cTn, solid line) and natriuretic peptide (NTproBNP, dashed line) [bottom panel], in relation to extent and timing of
tissue damage [top panel]
The magnitude of IMA elevation has been found to correlate with the number and frequency
of transluminal balloon inflations during the PCI procedure [33]. 34 patients received standard
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routine care for elective single vessel PCI for the management of stable angina pectoris. 44%
of patients received 1-4 balloon inflations whilst, 56% received >5 inflations. IMA concentra‐
tions were higher in those with more balloon inflations, higher pressure load of the balloon
and the longer the duration of the inflation. IMA is thus not only a marker of the occurrence
of ischemia but is also an indicator of the severity of the ischemic episode.
IMA concentrations are lower in patients who demonstrate angiographic evidence of collateral
vessels present in the coronary circulation, according to Rentrop’s classification [34]. IMA
levels post-PCI are higher than baseline, however post-PCI values are lower compared to post-
PCI values in those patients without a collateral circulation; irrespective of the extent of
coronary artery disease or those who underwent a large number of balloon inflations for longer
duration [35]. The lower IMA concentrations in patients with a collateral circulation likely
represent a cardioprotective effect against PCI-induced ischemia. IMA elevation is also
correlated to the need for subsequent revascularization [36]. Elevated IMA greater than 130
KU/L was associated with a higher frequency of target lesion revascularization at 4-years
follow-up in 60 patients who underwent a successful elective single vessel PCI for stable angina
pectoris at baseline. The accepted gold standard blood marker for myocardial ischemia is
myocardial lactate extraction. Simultaneous IMA and lactate was measured in 10 patients
undergoing PCI for chronic stable angina. Post-PCI IMA concentrations paralleled that of
transmyocardial lactate [32].
Elevation in serum IMA has been recorded following coronary vasospasm [37]. Twenty six
patients with variant angina underwent intracoronary ergonovine spasm provocation testing.
Arterial IMA concentrations were measured pre and post procedure and compared to 18
patients undergoing elective PCI and 10 patients with normal coronary angiography. IMA was
significantly elevated following drug induced coronary vasospasm compared to baseline and
elevated values detected coronary vasospasm with an area under the curve (AUC) of the
receiver operating characteristic (ROC) curve of 0.98 (95%CI 0.92-1.00). Other studies involving
invasive cardiac procedures have shown rises in IMA where ischemia might occur, occurring
concurrently with ECG changes in cardioversion[38], but show a variable picture when there
is non-ischemic myocardial damage as in cardiac ablation [39;40].
8.2. Measurement of ischemia modified albumin
The original biochemical test for IMA was known as the albumin cobalt binding (ACB®) assay.
This was developed by Ischemia Technologies Inc, Colorado, USA). The assay measures the
cobalt binding capacity of albumin in a sample of serum. A known amount of cobalt is added
to the patient serum sample. Dithiothreitol (DTT) is added which binds any remaining
unbound cobalt and the colorimetric change is measured spectrophotometrically. In serum
from non-ischaemic patients, cobalt binds to the N-terminus of HSA, leaving little free cobalt
to react with DTT and form a coloured product. Conversely, in serum of patients with ischemia,
cobalt does not bind to the N-terminus of modified HSA, leaving more free cobalt to react with
DTT and form a darker colour. As normal albumin will bind cobalt, the amount of free cobalt,
hence the absorbance will be proportional to the amount of IMA present (figure 4).
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Figure 4. Measurement of Ischemia Modified Albumin by the Albumin Cobalt Binding (ACB) assay. A known
amount of CoCl2 is added to a serum sample. DTT is added which binds unbound Co++ causing a colorimetric change
read spectrophotometrically.
The first generation assay was semi-automated and required a sample pre-treatment step
where 500μL of serum sample was added to an Eppendorf tube containing 0.45g CaCl2. The
sample was inverted twice and centrifuged at 1200g for 10 minutes. 300μL of supernatant was
removed for assay of IMA. For the assay, powdered DTT was provided which required
reconstitution in the ratio 15mg DTT: 10 mL diluent. The reconstituted reagent and power
required storage at 2-8oC and the working solution had a shelf life of 3-5 days. The second
generation of the assay used 7.5mg DTT to 10mL diluent. The third generation assay which
became commercially available did not contain the sample pre treatment step and the assay
kit contained a concentrated liquid form of DTT which was reconstituted in buffer with a fixed
volume 200 μL pipette.
The assay can be performed manually with a spectrophotometer, however it was also initially
automated on the Cobas MIRA Plus (Roche Diagnostics) automated spectrophotometer [41].
The assay has since been adapted for other automated clinical chemistry platforms includ‐
ing the LX-20 (Beckman Coulter, Brea, CO, USA) [42], Hitachi 911 (Hitachi, Japan) [43] Hitachi
7600 (Hitachi, Japan) [44] and the Konelab 20 (Thermo Scientific, United Kingdom) [45]. To
date a commercialised point of care device for IMA remains to be developed however a pre-
commercial  portable  spectrophotometer  and IMA assay  has  been  developed by  (Micro‐
wells Biotechnology Co. Ltd, Shanghai, China). In the Microwells assay, the DTT has been
replaced with a  stable  azo dye chromogen.  An automated method to measure ischemia
induced alterations of the binding capacity of HSA for nickel [27] has been described [46].
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The nickel binding assay correlated well to the ACB assay (r=0.5387, p<0.001) however the
AUC of the ROC curve was higher for the nickel binding assay (0.7582) compared to the
ACB assay  (0.7289)  suggesting  nickel  binding  has  a  superior  ability  to  discriminate  be‐
tween ACS and non-ACS compared to the ACB assay. There are rumours of an ELISA assay
for  IMA.  This  assay  is  not  validated  for  clinical  diagnostic  or  therapeutic  use  and  an
independent performance validation and comparison to the ACB assay does not appear in
the current literature. The development of an ELISA however is probably not valid given
the  rapid  alteration  and  return  to  baseline  of  IMA  following  ischemia,  suggesting  the
alteration is  transient and not a permanent change to a specific  epitope which could be
detected by an antibody.
The in vitro stability of the IMA has been shown to be two hours at either 4oC or 20°C, but
values increase significantly after four hours irrespective of the storage temperature [33].It is
likely that the changes are due to in vitro pH changes altering the metal binding capacity of
human serum albumin. Samples frozen at -20°C are stable although values have been reported
to be slightly higher once thawed, compared to freshly analysed samples [47]. The assay
incubation temperature can also affect cobalt binding to HSA and thus influence the IMA
concentration [48].
A study of 109 subjects (55 men and 54 women; age range, 20 to 85 years) to determine the
95th percentile reference range for IMA has been performed [49]. The concentrations ranged
from 25.7 to 84.5 KU/L with an upper 95th percentile of 80.2 KU/L. This study used the first
generation of the assay utilising the pre-handling sample preparation step. Further studies of
healthy subjects have reported higher IMA ranges. Abadie and colleagues demonstrated a
mean IMA value of 89 KU/L from 69 subjects with a mean age of 49 years [50] whilst Maguire
and colleagues demonstrated a 97.5th percentile of 110 KU/L [42] from a population of 81
healthy volunteers (28 men and 53 women aged 22-86 years). Values ranged from 82.0 to 110
KU/L and values were similar between males and females (99.1 vs 100.7 KU/L, p=0.12). The
biological variation of IMA has been studied [51].In a population of 17 apparently healthy
individuals (7 male, 10 female, aged 26-61 years), the within subject coefficient of variation
was 2.89% and the between subject coefficient of variation was 6.76%, calculated from weekly
blood draws performed at the same time by the same phlebotomist for 5 consecutive weeks.
Again there was no specific gender difference in IMA concentrations however the authors
reported statistically different IMA concentrations between Caucasian and Black populations,
with higher IMA concentrations in Black males and females compared to Caucasian counter‐
parts.
Total serum albumin concentrations might be expected to affect the performance of IMA
measurement. There is a relationship between IMA values and serum albumin concentration,
although this is much less marked across the reference interval for albumin [52]. The use of an
albumin adjusted correction has been proposed [53] although a reference interval study found
albumin correction to have little impact compared to other analytical factors [42]. It has been
reported that the changes in IMA observed in patients with chest pain was attributable only
to changes in the serum albumin concentration [54].
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8.3. Clinical utility of ischemia modified albumin in chest pain patients
Clinical  validation of  any test  for  ischemia is  difficult  as  there  is  currently  no accepted
diagnostic gold standard, although blood lactate has been used previously.In addition, there
is no predicate test which can be used against which to perform an initial validation. The
initial studies using IMA were based on the ability of an early measurement to predict the
final diagnosis of AMI as defined by the elevation of cardiac troponin at 6-12 hours post
chest pain. Two studies utilised the first generation pre-release ACB test and a third study
manufactured an in-house method. The first study examined acute coronary syndrome (ACS)
patients  and  utilised  serial  sampling  on  admission  and  two  subsequent  samples  [55].
Diagnostic sensitivity of the admission sample for a final diagnosis of AMI was 23.9% for
cardiac troponin I (cTnI) alone, 39.1% for IMA alone and 55.9% for the two combined. The
second study examined enrolled 256 ACS patients [49]. AUC of the ROC curve for the ACB
test  was 0.78 with a sensitivity and specificity of  83% and 69% respectively at  the opti‐
mised decision threshold for AMI. The third study enrolled 75 patients with ischemia and
92 non-ischemic patients [29]. IMA had poor predictive power in discriminating between
AMI  and  non-AMI  in  patients  with  underlying  ischemic  heart  disease  (AUC  of  0.66).
However, the test gave good discrimination between patients with or without ischemia. The
AUC for the ROC curve for diagnosis of ischemia was 0.95 with sensitivity of 94% and
specificity of 88%. In these initial studies there were significant problems with sample stability
and the assay involved in addition of calcium chloride and centrifugation as part of the
routine method. This made the method unsuitable from routine analysis and the assay was
reformulated.
The majority of patients who present to hospital with chest pain and suspected ACS are
eventually ruled out for acute myocardial infarction and active unstable coronary disease.
The ideal role of an ischemia marker would therefore be as rule out test.The most logical
place to use such a test is therefore in the ED.A study of ED presentations examined 208
patients the diagnostic sensitivity of IMA measurement alone was 82% at 46% specificity in
samples taken within the first 3 hours. The combination of ECG, cardiac troponin T (cTnT)
and IMA showed 95% sensitivity for diagnosis of ACS at presentation [56]. One year follow
up performed on this population demonstrated a survival disadvantage in patients with
IMA greater than the median concentration of the study group [57]. A subsequent study of
538 patients admitted to a chest pain evaluation unit found admission measurement of IMA
plus cTnT had 100% sensitivity for prediction of a final diagnosis of AMI [1].  The pres‐
ence of an elevated IMA and an elevated cTnT on admission predicted 21% risk of major
adverse cardiac events (MACE) compared to patients where both were not elevated, even
in  patients  where  the  final  diagnosis  excluded  AMI  by  troponin  based  criteria.  IMA
measurement appears to work best as part of a panel of other tests or a test sequence [50].
Admission measurement of IMA has been found to be superior to biomarkers of necrosis
and to show 97% sensitivity when combined with them. Not all investigators have consid‐
ered the diagnostic performance of IMA either alone or in combination with cardiac troponin,
or  other  biomarkers  of  necrosis,  to  be  adequate.  A  prospective  ED study enrolling  277
patients and using a positive IMA or troponin as the index test and an 8 hour troponin as
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the definitive test found only a 97.6% sensitivity with 97% negative predictive value. The
investigators did not consider this to be adequate when compared with troponin but did
not  provide  any  follow-up  data  [58].  A  second  large  study  prospectively  enrolling  189
patients  presenting  to  the  ED with  chest  pain  and found an elevated IMA was  a  poor
predictor of cardiac events within the next 72 hours [59]. Conversely, another study found
elevated IMA predicted long-term cardiac events [60]. The most consistent finding across
all studies of IMA is of a high negative predictive value. This has been highlighted in a
meta-analysis specifically examining the role of IMA as a rule out test [61]. The summar‐
ised data of over 1800 patients demonstrated a triple negative prediction test (non-diagnos‐
tic ECG, negative cTn and negative IMA) with a sensitivity and negative predictive value
for ACS of 94.4% and 97.1% respectively.
The prognostic value of IMA in the ACS setting has been investigated [57;60;62;63]. Using a
ROC derived cut off of 477 KU/L, Aparci and colleagues found significantly higher mortality
at one year in those who had serum IMA >477 KU/L, compared to those with IMA <477 KU/L
[60]. Furthermore, using cox regression modelling, IMA was related to mortality, independ‐
ently of the presence of hypertension, diabetes or advanced age. In a larger cohort of 245
consecutive attendances to the ED, in which there were 31 composite endpoint (cardiac death,
AMI or recurrent angina) at 30-days from presentation and 16 deaths at one year; the short
and long term ability of IMA to predict outcome was assessed. Short term survival was
significantly compromised in those with IMA > 93.3 KU/L compared to those with lower IMA
concentrations at both 30 days and 1 year [57]. Using the cohort of the French Nationwide
OPERA study IMA, cTn, CRP and BNP were measured within 24hours from admission in 471
patients hospitalized with AMI. Using a primary end point of death, resuscitated cardiac arrest,
recurrent AMI or ischemia, heart failure or stroke, 75 in-hospital events and 144 events at 1
year were recorded. Using quartile analysis, 40% of patients reached the end point with IMA
concentrations in the highest quartile (>104 KU/L), compared to only 20% of patients in the
lowest quartile of 83 KU/L [63]. In those STEMI patients who are treated with primary PCI,
IMA is a powerful predictor of 30-day mortality however it does not add to the validated
Thrombolysis In Myocardial Infarction (TIMI) risk score [64].
8.4. Clinical utility of ischemia modified albumin in non–chest pain patients
Any marker associated with pathological processes upstream of cardiac necrosis will invari‐
ably suffer from a lack of specificity; unlike the cardiac troponins for cardiac necrosis. The
further upstream in the ischemic continuum the more likely is the lack of cardiac specificity of
the biomarker. Elevations in circulating IMA concentrations are not specific for myocardial
ischemia. Mechanistically, IMA can be generated during any ischemic process within the body.
A comprehensive review of IMA elevations in non-cardiac conditions is beyond the scope of
this chapter but an in-depth summary is given in table 2.Those conditions that have been
studied most are explained in more detail below.
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Condition
Carbon monoxide poisoning
Congestive cardiac failure
Chronic kidney disease
Deep vein thrombosis
Diabetes Mellitus
Hypercholesterolaemia
Intermittent claudication
Ischemic bowel
Liver cirrhosis
Neural tube defects
Obesity
Pleural effusion
Polycystic ovary syndrome
Polycythemia vera
Preeclampsia
Pulmonary embolism
Skeletal muscle ischemia
Stroke
b-thalassemia
Testicular torsion
Uterine artery embolisation for fibroids
Table 2. Increased serum IMA concentrations in conditions other than acute coronary syndrome.
8.4.1. Skeletal muscle ischemia
Studies of subjects with skeletal muscle ischemia have produced contradictory results. In
healthy subjects undergoing arduous physical exertion, IMA has been reported to fall imme‐
diately post exercise and then subsequently rise [65-67] or return to normal [68]. Subjects
undergoing a forearm ischemia test when the forearm muscles are exercised for 1 minute with
the external compression of the arm blood supply showed a fall in IMA, maximal at 3 minutes
from the test, returning to baseline by 30 minutes [69]. A similar rise in serum lactate occurred.
Conversely during standardized exercise in a plantar flexion pedal combined with inflation
of a femoral blood pressure cuff (at 0, 60, 90, 120 and 150 mmHg) to induce calf muscle ischemia
an increase in IMA was observed after release of the cuff and returned to baseline within 30
minutes [70]. Peri-operative skeletal muscle ischemia induced by femoral blood pressure cuff
being inflated to 300 mmHg in 23 patients undergoing arthroscopic knee surgery. Increased
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IMA and myoglobin and decreased albumin were observed following release of the cuff [71].
In patients with peripheral vascular disease (PVD) undergoing a treadmill walk test, a decrease
in serum IMA immediately post-test has been documented [72;73]. In 40 consecutive patients
undergoing exercise electrocardiography, a significant decrease in IMA at peak exercise then
a subsequent rise in IMA has been observed, however there was no difference in IMA
concentrations between those patients with positive and negative stress test results [74].
Revascularisation for PVD is accompanied by a post procedural rise in IMA [72;73;75]. In
skeletal muscle ischemia, an initial fall with subsequent rise appears to be a consistent finding
without adequate explanation. Smooth muscle ischemia does not appear to be associated with
a rise in IMA [76]. The effect of skeletal muscle on ischemia will limit the application of IMA
measurement after cardiac stress testing for detection of myocardial ischemia and may explain
the inconsistent findings[54;74;77;78].
8.4.2. Ischemic stroke
Patients with acute ischemic stroke demonstrate abnormalities in a number of biomarkers of
nitrosative and oxidative stress. In 41 patients with ischemic stroke, Senes and colleagues
demonstrate that nitrate, IMA and thiobarbituric acid-reactive substances (TBARS) concen‐
trations are significantly increased compared to 37 age and gender matched controls [79]. In a
larger cohort of 118 patients presenting within 3 hours of neurological deficit, IMA was
elevated in those with cerebral infarction and intracranial haemorrhage (ICH) but normal
reference values were observed in those with transient ischemic attacks (TIA) lasting less than
1 hour or those with epileptic seizures [80]. Within 24 hours of injury IMA increased during
cerebral infarction but not in intracranial haemorrhage and may offer diagnostic utility in the
differential diagnosis of neurological deficit. IMA also correlated with National Institutes of
Health Stroke Scale (NIHSS) Score in both cerebral infarction and ICH. Conversely, Herisson
and colleagues did not demonstrate a causal relationship between IMA or heart type fatty acid
binding protein and NIHSS score or stroke volume [81]. Ahn and colleagues have utilised an
albumin-adjusted IMA index for the early detection of ischemic stroke [82]. In 52 patients, 28
(54%) with Ischemic stroke, 24 (46%) non-stroke, the AUC of ROC curve analysis was 0.928 for
IMA but 0.99 for albumin-adjusted IMA index. The sensitivity and specificity of the IMA index
was superior to IMA concentration alone.
8.4.3. Pulmonary embolus
Pulmonary  embolus  (PE)  is  an  acute  medical  emergency estimated to  occur  in  3.5/1000
hospitalized patients.  Patients  experience  sudden onset  dyspnoea,  tachypnoea,  pleuritic-
type chest pain, cyanosis and haemoptysis. PE has an associated mortality of 26%. Diagno‐
sis is primarily based on typical clinical presentation using the Wells and Geneva clinical
probability scores. D-dimer measurement and pulmonary angiography are often clinically
useful. The ECG can demonstrate acute corpulmonale in large PE’s but lacks specificity. IMA
has been measured in a number of studies of PE patients. Turedi and colleagues [83] have
demonstrated that IMA was significantly elevated in 30 PE patients compared to 30 healthy
controls and adequately discriminated between the presence and absence of PE. The positive
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predictive value of IMA for PE is higher than that for D-dimer (79.4% compared to 69.4%)
and in combination with the Wells and Geneva criteria,  IMA offers an alternative to D-
dimer testing [84].
8.4.4. Chronic kidney disease
Patients with chronic kidney disease (CKD) have a reduced life span compared to those
without renal disease. Mortality rates are highest in those receiving haemodialysis as renal
replacement therapy (RRT). Cardiovascular mortality accounts for the majority of renal deaths.
Between 2001 and 2006, 24% of deaths in UK RRT patients were due to ischemic heart disease
[85]. This rate is consistent with data from other countries. Cardiovascular morbidity is also
increased. 55% of patients receiving haemodialysis RRT also have concomitant congestive
cardiac failure. [86]. IMA levels have been determined in patients with CKD [87-89] and in
patients receiving haemodialysis (HD) [90-94].
In  2006,  Sharma  and  colleagues  demonstrated  that  patients  with  elevated  IMA  have  a
significantly  large  left  ventricle,  decreased  systolic  function  and  greater  estimated  left
ventricular  filling pressure [88].  Further,  in  multivariate  analysis,  a  positive dobutamine
stress echocardiogram (DSE) combined with elevated IMA and cTnT and E/Ea ratio were
independent prognostic factors for death. IMA values increase significantly in those patients
with a positive DSE compared to those with no ischemic response [87]. In a modestly small
study of 17 anaemic CKD patients and 19 controls, Cichota and colleagues demonstrated
that IMA increased in patients compared to the control group. IMA correlated to lactate,
haemoglobin and creatinine [89].
Pre and post-HD IMA concentrations are significantly correlated [90], however in this study
IMA concentrations were not significantly different between those CKD patients with or
without  ischemic  heart  disease,  diabetes  mellitus  or  peripheral  vascular  disease.  Fast
intravenous iron administration during HD is associated with oxidative stress and inflamma‐
tion.  In a study of  20 HD patients receiving slow intravenous iron administration,  IMA
concentrations were significantly increased across three HD sessions independently of slow
i.v. iron administration [91].Following adjustment of albumin by two methods, post dialysis
IMA levels remain significantly increased following HD [92].  Paroxonase-1 (PON-1) is  a
calcium dependent esterase (arylesterase, aromatic esterase 1, serum aryldialkylpohospha‐
tase  1,  EC 3.1.8.1)  is  a  major  anti-atherosclerotic  component  of  HDL cholesterol.  PON-1
concentrations are lower in CKD patients with and without haemodialysis RRT compared
to controls suggesting chronic oxidative stress and accelerated atherosclerosis are a feature
of  CKD.  In  a  pilot  study  of  CKD  patients  receiving  HD,  PON-1  concentrations  were
significantly and inversely correlated to IMA suggesting an oxidative stress and ischemic
process occurs during HD [93]. Recently Albarello and colleagues have evaluated the effect
of IMA and protein carbonyl groups as markers of protein oxidation in 23 CKD patients
receiving HD. The authors confirm previous reports of higher IMA post-HD than pre-HD
and observed a significant correlation between IMA and protein carbonyl groups, attribut‐
ed to oxidative stress associated with HD [94].
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8.4.5. Hyperlipidaemia and obesity
IMA measurement may be of benefit in hypercholesterolaemic patients. IMA is correlated to
cholesterol, low density lipoprotein (LDL) and antibodies to oxidised LDL (ox-LDL) [24]. In a
study of 37 subjects with hypercholesterolaemia compared to 37 controls, Duarte and collea‐
gues [95] confirm these findings observing IMA correlations to cholesterol, LDL ox-LDL
antibodies and to high sensitivity C-reactive protein, suggesting that hypercholesterolaemia
is associated with inflammatory and oxidative stress processes, contributing to the advance‐
ment of atherosclerosis. IMA is related to the presence of metabolic syndrome independently
of age, gender, presence of diabetes or hypercholesterolaemia[96]. Furthermore, the use of 10
mg/day ezetimibe immunotherapy for a duration of 12 weeks in 31 hypercholesterolaemic
patients reduced both LDL cholesterol and IMA [97]. The reduction of IMA was independent
of the reduction in LDL suggesting that ezetimibe may reduce the burden of oxidative stress
in hypercholesterolaemia.
IMA concentrations are higher in obese subjects, with a positive correlation between IMA and
body mass index (BMI).In a large study of 148 volunteers in Brazil; subjects were classified as
normal, overweight or obese, defined as BMI of 18.5-24.9, 25.0-29.9 and >30 kg/m2 respectively.
IMA concentrations increased exponentially between the three groups, the highest being in
those subjects with BMI >30 kg/m2. Similar findings have been demonstrated in obese post‐
menopausal women where IMA and IMA: Albumin ratio are higher in those subjects with BMI
26-32 kg/m2 compared to those with BMI 21-25 kg/m2. The obese concentrations were similar
to those with documented coronary artery disease but normal BMI. In the obese women IMA
was positively correlated to BMI, hs-CRP, insulin concentrations and homeostasis assessment
model score [98].
8.4.6. Diabetes mellitus
Patients with type 2 diabetes mellitus who demonstrate poor glycaemic control have higher
IMA concentrations than those with good glycaemic control. IMA was significantly higher in
76 diabetic patients compared to 25 control subjects and IMA concentrations are correlated to
HbA1c [99], glucose and hs-CRP [100]. Conversely, Dahiya and colleagues suggest no
significant changes in IMA occur in 60 newly diagnosed type 2 diabetics, compared to 30
control subjects [101]. Diabetic patients who undertake chronic exercise for three months
demonstrate lower post exercise IMA concentrations suggesting that exercise alleviates some
of the oxidative stress associated with diabetes mellitus [102].
8.4.7. Bowel ischemia
Bowel (mesenteric) ischemia occurs infrequently however if not recognised early, carries a
devastatingly high mortality. The presentation is often characterised by generalised abdominal
pain, fever, diarrhoea or constipation, tachycardia, hematochezia (blood per rectum), nausea
and vomiting. Diagnosis is difficult due to non specific signs and symptoms, plain x-ray or
laboratory tests (increased white blood cell count and serum lactic acid). Mesenteric angiog‐
raphy is considered to be the gold standard test which can differentiate between embolic,
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thrombotic or nonocclusive ischemia. In a preliminary study of 26 patients presenting with
symptoms of internal ischemia, Polk and colleagues [103] identified 12 with a positive clinical
diagnosis. Positive patients had higher IMA concentrations than those without intestinal
ischemia. IMA detected bowel ischemia with a sensitivity of 100% and a specificity of 86%. In
a case-controlled study from Turkey, Gunduz and colleagues [104] demonstrated that pre-
operative IMA concentrations were significantly higher in patients with thromboembolic
occlusion of the superior mesenteric artery (SMA) compared to an age-matched control group
of healthy volunteers. A number of animal studies of mesenteric ischemia have provided
conflicting results. In a Wistar rat model [105] a time dependent response in IMA in mesenteric
ischemia has been demonstrated. 36 mature female rats underwent either simple laparotomy
in the control groups or laparotomy followed by clamping of the SMA in the subject group.
IMA concentrations were highest 6 hours from ischemic onset, however IMA at 30 minutes
and 2 hours were also significantly higher in the clamped group compared to the control group.
Elevations of IMA tracked changes in both lactate and malondialdehyde. A similar time
dependent change in IMA was demonstrated in New Zealand rabbits undergoing ligation of
the SMA compared to either a control group or those undergoing a sham procedure [106]with
elevation of IMA at 2 and 6 hours significantly higher than baseline and higher than IMA
concentrations in the control rabbits. IMA concentrations mimicked elevations in serum IL-6
with elevated IL-6 in the ischemia group at 1, 3 and 6 hours, but no elevations in the sham
operated or control group. In a further study of mesenteric ischemia in a Wistar rat model,
Uygun and colleagues [107] demonstrated similar IMA concentrations in control, sham, 2-hour
and 6-hour post-SMA ischemia refuting the previous animal studies. It seems likely that IMA
may offer additional diagnostic value in the early presentation of mesenteric ischemia. Further
prospective studies are required to assess both the diagnostic and prognostic ability of IMA
in conjunction with mesenteric angiography to detect bowel ischemia.
8.4.8. Obstetric and gynaecological use of IMA
The care of women and their unborn child during pregnancy is greatly challenging for
obstetricians. The adult can interact and provide a history of signs and symptoms whereas the
unborn child can only be examined indirectly by means of imaging, foetal heart monitors and
a limited number of direct interventions. Women achieving spontaneous preterm (<37 weeks)
labour account for 10% of all births and are attributable to 75% of neonatal deaths. The foetus
relies entirely on the maternal placenta for O2/CO2 exchange. This delicate dependence,
between the placenta and the foetus is crucial to normal healthy growth. Any malfunction or
disruption to the adequate supply of oxygen can cause hypoxia and potentially fatal acidosis.
A limited degree of acidosis is well tolerated by the foetus; however chronic acidosis or hypoxia
may lead to a significant mortality and morbidity with potential log-term sequelae. Currently
the mechanism of foetal hypoxia and acidosis is unclear, and physiological consequence of
foetal acidosis is believed to target the cell energy availability and /or cell poisoning.
During pregnancy plasma proteins change markedly due to increased plasma volume,
increased renal blood flow and altered protein synthesis in response to hormonal changes.
Plasma volume expansion of up to 45% [1300mL) compared to the non-pregnant state causes
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an overall net decrease in plasma protein concentration by 10-12 g/L which is reached around
week 28 of gestation. The predominant cause of lowered albumin is dilutional, oestrogen is
known to affect albumin. The alteration to plasma albumin concentrations throughout the
pregnancy period is shown in table 3. The lower concentration of albumin also results in an
apparent decrease in substances normally bound to this protein.
Time point Mean albumin concentration (g/L) Reference interval(g/L)
Non pregnant control 41 36-46
12 weeks 38 33-43
18 weeks 35 30-39
24 weeks 33 29-37
28 weeks 32 28-37
32 weeks 32 38-36
36 weeks 32 38-36
Full term 32 26-38
1 day post partum 29 23-38
6 weeks post partum 42 37-47
Table 3. Alteration to plasma HSA concentrations during the gestational period.
The HSA reference interval in the full term healthy neonate between term and day 4 is 28-44
g/L. Albumin concentrations increase a little from birth to puberty where the adolescent
reference interval (day 4 to 14 years) is 38-54 g/L.
Current experimental studies suggest that foetal development occurs in a hypoxic intrauterine
environment and the presence of reperfusion and oxidative stress is believed to be crucial for
trophoblast development [108]. Trophoblast invasion of the maternal spiral arteries allows the
increase of uterine blood supply necessary to maintain the pregnant state. Serum IMA during
normal pregnancy is elevated compared to non-pregnant controls [109-112]. Prefumo and
colleagues [109] demonstrate supra-physiological IMA concentrations in early normal
pregnancy (11-13 weeks of gestation) suggesting that trophoblast development occurs in a
hypoxic uterus. In a large population of 117 pregnant women compared to non-pregnant
healthy women, Guven and colleagues demonstrated a cross-sectional elevation in IMA in
pregnant women. IMA increased significantly through each trimester. Further, there the
authors demonstrated a significant negative correlation between IMA and HSA, suggesting
that elevated IMA in pregnancy represents a physiologic state of oxidative stress.
Increased intrauterine hypoxia predisposes to defective endovascular trophoblast invasion of
the maternal spiral arteries which may possibly lead to the development of pre-eclampsia; a
hypertensive state (>140/90 mmHg) associated with significant proteinuria (≥300mg/dL). Pre-
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eclampsia affects 6-8% of pregnancies worldwide. Papageorghiou and colleagues have
demonstrated that first trimester serum IMA are significantly higher in women who develop
pre-eclampsia compared to those with a normal pregnancy [113]. Both IMA and normalised
IMA (IMA: Albumin ratio) were higher in 20 pre-eclamptic women compared to 22 normal
pregnancies [112]. These data suggest IMA could be a biological marker of pre-eclampsia
however larger studies are required to fully characterise the supra-normal IMA and normal‐
ised IMA reference interval in normal pregnancy.
Maternal IMA and normalised IMA concentrations are also increased in women with recurrent
pregnancy loss (two or more unexplained miscarriages in the first trimester) compared to
healthy pregnancy [114], suggesting that an increase of intrauterine oxidative stress and
hypoxia contribute to placental deficiency and subsequently recurrent early miscarriage.
The use of umbilical cord blood for IMA has also been examined. Neonatal cord blood IMA
concentrations are higher than IMA concentrations in healthy adults [115] but is not attribut‐
able to changes in HSA concentration. Elevated fetal IMA may reflect transient localised
ischemia from external forces exerted on the foetus during labour. In a case-control study of
26 newborns, 12 delivered at normal term and 14 with complicated labour or delivered pre-
term; cord blood IMA concentrations were significantly higher (50%) than those with un‐
eventful deliveries, suggesting IMA is a marker of fetal distress. Doubly-clamped cord blood
IMA concentrations are similar in intrauterine growth restriction, compared to those delivered
with appropriate for gestational age full-term pregnancies [116]. The similar IMA concentra‐
tions may be due to the ‘brain sparing effect’ accompanied by oligohydraminos (deficiency in
amniotic fluid), which is characterised by rerouting the blood supply and the nutrient to vital
organs such as the heart, brain and adrenal glands. IMA concentrations in cord blood are higher
following caesarean section compared to vaginal delivery and in multigravida compared to
primigravida [116] and may be attributable to higher oxidative stress on both accounts.
Cigarette smoking during the gestational period alters the oxidant/antioxidant balance in
favour of oxidative stress. In response, IMA and MDA concentrations in pregnant smokers are
significantly higher and vitamins A and E, SOD and total antioxidant capacityare significantly
lower, compared to non-smoking pregnant women [117].
9. Cardiac troponin: Ischemia or necrosis?
The release of cTn was previously thought to occur only in the presence of cell necrosis. The
recent development of high sensitivity cTn (hs-cTn) assays has lead to a) the ability to define
a true 99th percentile and near-Gaussian distribution in the healthy population and b) earlier
diagnosis of AMI with increased sensitivity but at the cost of specificity [118]. A number of
clinical and physiological situations have arisen which suggests cTn is released during
ischemia in the absence of overt necrosis [119]. These include patients who present with
superventricular tachycardia [120] without electrocardiographic changes; in patients with
pulmonary embolism [121] where cTn release may indicate a reversible release and under
physiological strain following endurance exercise [122]. In all cases the kinetic release is
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shortlived with post even values returning to baseline normally within a 24 hour window.
Although the mechanisms have not been elucidated postulates include, physiological cardio‐
myocyte turnover, cellular release of proteolytic degradation products, alteration in plasma
membrane permeability and the formation of membranous secretion vesicles containing
intracellular derived cTn.
10. Conclusions
Although there are a number of candidate biomarkers for the detection of cardiac ischemia in
the research and development world; biomarkers upstream of cardiac cell necrosis lack
specificity. They are therefore, at best additive to the diagnostic and prognostic utility of cTn
in the early investigation of patients presenting with ischemic type symptoms. The clinical
utility of novel biomarkers of ischemia lies in their negative predictive value rather than their
ability to adequately rule-in ACS. Given the development of sensitive cTn methods, further
work is needed to characterise the release mechanisms of cTn from cardiomyocytes.
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